Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-Current Assets (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non-Current Assets for 14 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 21576.92% to $2.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 4597.14% increase, with the full-year FY2024 number at $11000.0, down 52.17% from a year prior.
  • Non-Current Assets was $2.8 million for Q3 2025 at Traws Pharma, up from $252000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.8 million in Q3 2025 to a low of $11000.0 in Q4 2024.
  • A 5-year average of $213210.5 and a median of $29000.0 in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 77.84% in 2022, then surged 21576.92% in 2025.
  • Traws Pharma's Non-Current Assets stood at $48000.0 in 2021, then tumbled by 47.92% to $25000.0 in 2022, then fell by 8.0% to $23000.0 in 2023, then tumbled by 52.17% to $11000.0 in 2024, then surged by 25518.18% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Non-Current Assets are $2.8 million (Q3 2025), $252000.0 (Q2 2025), and $207000.0 (Q1 2025).